Programmable mRNA 3′UTR Engineering Restores MHC-I and Overcomes Immune Evasion in Prostate Cancer
核心洞察
Researchers developed 3′UTRCES, a CRISPR/dCas13 RNA-editing platform that precisely manipulates mRNA alternative polyadenylation to restore MHC-I (搜索) expression in immune-resistant prostate tumors.
The study identifies tumor-specific 3′UTR shortening in the E3 ubiquitin ligase adaptor SPSB1 (搜索) as a novel mechanism driving MHC-I (搜索) degradation and immune evasion without affecting PD-L1 (搜索) levels.
Lipid nanoparticle delivery of 3′UTRCES constructs reversed aberrant SPSB1 (搜索) 3′UTR shortening, restored MHC-I (搜索) surface expression, and enhanced CD8 T cell infiltration in syngeneic mouse models.
A groundbreaking study published in Nature Biomedical Engineering unveils a programmable RNA engineering platform capable of restoring immune recognition in notoriously immune-resistant prostate tumors. The research, led by Huang, Yuan, Li, and colleagues, introduces the 3′UTR CRISPR/dCas13 system (3′UTRCES)—an advanced RNA-editing tool that precisely manipulates mRNA alternative polyadenylation (APA) to revive expression of major histocompatibility complex class I (MHC-I (搜索)) molecules, the critical sentinels of immune surveillance routinely downregulated in these malignancies.
Prostate cancer (搜索) and analogous immune-cold tumors have long resisted immune checkpoint inhibitor therapies, a frontline strategy in modern oncology. A primary culprit in this resistance is diminished presentation of tumor-specific antigens on MHC-I (搜索) molecules, which are intrinsically responsible for flagging abnormal cells to cytotoxic CD8 T cells. Without adequate MHC-I display, malignant cells evade immune detection, rendering checkpoint blockade largely ineffective. Despite the clinical significance, no therapies have yet emerged that selectively restore MHC-I expression, underscoring a critical unmet medical need.
A Novel RNA-Editing Platform: 3′UTRCES
Unlike conventional gene editing tools that alter DNA sequences, 3′UTRCES uniquely targets RNA transcripts' polyadenylation sites to manipulate APA patterns—a post-transcriptional regulatory mechanism influencing mRNA stability, localization, and translation. The system leverages a catalytically inactive Cas13 (dCas13) fused to programmable effectors, reprogramming 3′UTR architecture to reinstate normal gene expression profiles critical for immune function.
The investigative team designed guide RNAs (gRNAs) targeting the proximal polyadenylation site (pPAS) of specific genes. By directing the dCas13b complex to block cleavage and polyadenylation factor access at these sites, 3′UTRCES effectively shifts polyadenylation from proximal to distal sites, thereby lengthening the 3′UTR. This mechanistic precision was validated through cross-linking immunoprecipitation experiments demonstrating enriched dCas13b binding on pPAS regions and decreased binding of CPA factors following 3′UTRCES treatment.
SPSB1 (搜索): A Newly Identified Driver of Immune Evasion
Central to the discovery is the identification of tumor-specific 3′UTR shortening in SPSB1 (搜索), an E3 ubiquitin ligase adaptor previously unlinked to immune modulation. Through systematic screening of 370 3′UTR shortening events observed in castration-resistant prostate cancer (搜索) (CRPC) compared with androgen-dependent prostate cancer (搜索) (ADPC) patient tissues, the researchers found that 12.4% significantly correlated with biochemical recurrence (BCR) survival (P < 0.05). Notably, 3′UTR shortening in 44 of 46 candidate genes (96%) correlated with shorter time to BCR survival.
SPSB1 (搜索) emerged as a key driver. The study demonstrated that SPSB1 interacts directly with MHC-I (搜索) molecules (HLA-A, HLA-B, and HLA-C) as well as E3 ligase complex components including Cul2, Elongin C, and RBX1. This interaction promotes ubiquitination and subsequent degradation of MHC-I proteins. Spearman's rank correlation analysis of the Beltran+SU2C CRPC cohort revealed a significant association between SPSB1 expression and MHC-I gene expression levels. In clinical tissue samples, MHC-I immunostaining was significantly reduced in CRPC tissues (n=24) compared with ADPC tissues (n=49, P < 0.001).
Critically, SPSB1 (搜索)-mediated MHC-I (搜索) degradation occurred without affecting programmed death-ligand 1 (PD-L1 (搜索)) levels. Flow cytometry analyses confirmed that 3′UTRCES-Spsb1 treatment did not alter surface PD-L1 on Pten−/−;Smad4−/−, Pten−/−;P53−/−;Smad4−/−, or Pten−/−;Rb−/− murine prostate cancer (搜索) cells, indicating selective restoration of antigen presentation machinery.
Preclinical Efficacy and Immune Synergy
The team deployed lipid nanoparticle (LNP) delivery of 3′UTRCES constructs into syngeneic mouse models harboring prostate tumors. In 22Rv1 xenograft models, intratumoral injection of TT3 LNP (搜索) encapsulating 3′UTRCES-SPSB1 (搜索)-g5 or -g6 significantly reduced tumor weights compared with control treatments (P < 0.01). In HMVP2 engrafted tumors, both g5 and g6 constructs decreased tumor weights, with corresponding reductions in the proximal/distal Spsb1 polyA usage ratio and Spsb1 protein levels.
The therapeutic intervention restored MHC-I (搜索) surface expression on tumor cells. In multiple genetically engineered murine prostate cancer (搜索) lines—including Pten−/−;Smad4−/−, Pten−/−;P53−/−;Smad4−/−, and Pten−/−;Rb−/− cells—3′UTRCES-Spsb1 (搜索) significantly increased surface H-2Kb levels (P < 0.05 to P < 0.0001). This restoration of antigen presentation reinvigorated CD8 T cell-mediated killing: in co-culture experiments with OT-1 CD8 T cells, 3′UTRCES-Spsb1-treated tumor cells showed significantly reduced viability at increasing T cell-to-target cell ratios.
When combined with anti-PD-1/anti-CTLA4 immune checkpoint blockade, 3′UTRCES-Spsb1 (搜索) treatment produced superior tumor growth inhibition in both Pten−/−;P53−/− and HMVP2 syngeneic models compared with either modality alone. The combination increased CD45-positive leukocyte infiltration within tumors. Importantly, the antitumor efficacy was abrogated in Tcrα and Tcrβ knockout mice lacking functional T cells, as well as upon CD8 T cell depletion, confirming the essential role of adaptive immunity. Furthermore, H2-k1 knockout in HMVP2 cells eliminated the therapeutic benefit, directly linking MHC-I (搜索) restoration to treatment efficacy.
Safety and Translational Potential
Toxicity evaluation in HMVP2 allograft-bearing mice treated for two weeks revealed no significant abnormalities in complete blood counts (RBC, WBC, HGB, PLT), hepatic function (ALT, AST), or renal function (CREAT, BUN) across treatment groups. Body weights remained stable, and H&E staining of major organs—including heart, liver, spleen, lung, and kidney—showed no histopathological changes, supporting the safety profile of the LNP-3′UTRCES approach.
The implications of this study extend beyond prostate cancer (搜索). By precisely tailoring RNA isoforms through 3′UTRCES, it becomes feasible to rectify pathological gene expression patterns without permanent genomic alterations, minimizing off-target effects and paving the way for tunable, reversible therapies. The researchers posit that similar APA-driven immune escape mechanisms may underpin resistance in other malignancies characterized as immune-cold or immunologically excluded.
This work confronts a longstanding conceptual bottleneck—the absence of clinically viable modalities to selectively restore MHC-I (搜索) expression. By restoring the tumor's antigen-presenting capacity, 3′UTRCES synergizes with immune checkpoint blockade, reinvigorating exhausted cytotoxic T cells and promoting tumor clearance. As the field gravitates toward RNA-based therapeutics, leveraging LNP delivery systems in oncology sets a precedent for future innovations combining synthetic biology and immunotherapy.